

## Epidemiological patterns, diagnosis and management of Chronic myeloid leukemia

**Vasile Musteata**

State University of Medicine and Pharmacy, Republic of Moldova

One hundred and twenty-five CML patients were followed up at the Institute of Oncology of Moldova between 2008 and 2012. The diagnosis was asserted by cytogenetic analysis of the bone marrow cells and real-time PCR in chronic phase in 113 (90.4%) patients, in accelerated and acute phases in 12 (9.6%) patients. Of 74 (59.2%) imatinib mesylate (IM)-treated patients, 65 (87.8%) were in chronic phase. IM was used in 11 (14.9%) cases as a front-line therapy and in 63 (86.1%) cases of the relapse or resistance to conventional chemotherapy (CCT). The extrapolation showed that in spite of the slow increase of the incidence (2010 – 0.81‰, 2014 – 0.83‰) the prevalence of CML should grow progressively (2004 – 2.11‰, 2010 – 3.40‰, 2014 – 4.16‰). The patient's age ranged from 19 to 81 years, with the commonly affected age group of 40 – 49 years (27.4±4.89%). The median age was 46.1±2.13 years old, that indicated the frequent involvement of the workable population. The median male/female ratio was 1.4:1. The majority of patients (66.7±5.14%) were heavily exposed to insolation. Complete hematologic response was obtained in 63 (85.1%) patients within 1 – 2 months of IM therapy, and proved to be superior ( $p<0.05$ ) to that obtained with CCT and IFN- $\alpha$  (14 (27.5%) patients). The overall 5-year survival and relapse-free survival at 18 months were higher ( $p<0.05$ ) in patients treated with IM (87.9% and 82% respectively) than in patients managed with CCT (57.3% and 20.5% respectively). The overall 3-year survival proved to be higher ( $p<0.05$ ) in females (66%) as compared with males (51%).

### Biography

Vasile Musteata had completed his Ph.D. and MPH at the age of 30 years and 39 years respectively and did his postdoctoral studies at the State University of Medicine and Pharmacy "N. Testemitanu" from the Republic of Moldova. He is the associate professor and deputy head for education at the university department of Hematology and Oncology, the GIPAP manager and ESMO National Representative for Moldova. He has published more than 100 articles and abstracts in reputed journals/abstract books and has been serving as an editorial board member of the *Journal of BUON*.

[vmusteata@yahoo.co.uk](mailto:vmusteata@yahoo.co.uk)